Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06641869
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-10
Brief Title:
Study of PCC1 and Senolytic Complex Cellumiva for Skin Rejuvenation
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A 12-week Randomized Open-label Study of PCC1 and Senolytic Complex Cellumiva in Healthy Volunteers for Skin Rejuvenation
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial will assess the efficacy of PCC1 and the Senolytic Complex Cellumiva for skin rejuvenation The primary objective is to determine whether these interventions enhance skin barrier function reduce wrinkles and improve skin texture and radiance over a 12-week period The study will involve healthy participants applying the treatments and undergoing assessments at baseline 6 weeks and 12 weeks Secondary objectives include evaluating the safety and tolerability of PCC1 and Cellumiva with any adverse effects closely monitored during the trial
Detailed Description:
As skin ages intrinsic and extrinsic factors contribute to cellular senescence disrupting the skins structure and function Senescent cells accumulate in the skin leading to the secretion of senescence-associated secretory phenotype SASP factors which promote inflammation and degrade extracellular matrix proteins like collagen These changes result in wrinkles loss of elasticity and reduced skin barrier function The study explores anti-senescence strategies using senolytic agents that selectively eliminate senescent cells aiming to rejuvenate the skin Compounds like PCC1 and Cellumiva have shown promise in targeting senescent cells by inducing apoptosis and reducing SASP expression offering a novel approach to skin aging therapy
This clinical trial is designed to evaluate the efficacy and safety of PCC1 and the senolytic complex Cellumiva in skin rejuvenation over 12 weeks Healthy female participants aged 45-65 will be randomly assigned to receive PCC1 Cellumiva a blend including procyanidin C1 Pterostilbene and Spermidine or a placebo The study will measure skin barrier function wrinkle reduction and textureradiance improvements using imaging technologies and participant feedback Safety will also be monitored through adverse event reporting
This clinical trial is designed to evaluate the efficacy and safety of PCC1 and the senolytic complex Cellumiva in skin rejuvenation over 12 weeks Healthy female participants aged 45-65 will be randomly assigned to receive PCC1 Cellumiva a blend including procyanidin C1 Pterostilbene and Spermidine or a placebo The study will measure skin barrier function wrinkle reduction and textureradiance improvements using imaging technologies and participant feedback Safety will also be monitored through adverse event reporting
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None